HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hansen, C. L. Articles by Iskandrian, A. S. Search for Related Content PubMed PubMed Citation Articles by Hansen, C. L. Articles by Iskandrian, A. S.

Prediction of Improvement in Left Ventricular Function with Iodine-123-IPPA after Coronary Revascularization

Temple University Hospital, Philadelphia, Pennsylvania
Philadelphia Heart Institute, Philadelphia, Pennsylvania
Albert Einstein Medical Center, Philadelphia, Pennsylvania
Medical College Hospitals, Philadelphia, Pennsylvania

Correspondence: For correspondence or reprints contact: Christopher L. Hansen, MD, Section of Cardiology, Temple University Hospital, 3401 N. Broad St., Philadelphia, PA 19140.

ABSTRACT

Iodine-123-phenylpentadecanoic acid (IPPA) is a synthetic long-chain fatty acid suitable for myocardial imaging. This study is the result of a Phase I/II trial to evaluate IPPA's ability to predict functional recovery in patients undergoing coronary revascularization. Methods: Twenty-three patients with documented coronary disease underwent sequential SPECT imaging with IPPA before and radionuclide ventriculography both before and 8 wk after revascularization. Software was developed to evaluate myocardial IPPA metabolism and to determine the fraction of the left ventricle with intermediate metabolism. Results: There was a significant correlation between initial IPPA uptake and final LVEF. The fractional area of the left ventricle demonstrating IPPA metabolism in the intermediate metabolic range was significantly higher in patients who demonstrated a 5% or greater increase in EF after revascularization (0.90 ± 0.08 versus 0.78 ± 0.17, p = 0.04). When only the patients who received complete revascularization were evaluated, there was a more significant difference (improved 0.92 ± 0.05 versus 0.74 ± 0.17, p = 0.011). Taking a lower limit of 1 s.d. from the mean, (87%) the six patients who had 5% increase in LVEF after revascularization had more than 87% of the left ventricle in the intermediate metabolic range, whereas seven of ten patients whose change in LVEF was <5% had less than 87% in the intermediate metabolic range (p = 0.011). Conclusion: In this initial experience, the amount of myocardium in the intermediate metabolic range is associated with improvement in LVEF after revascularization, especially in patients receiving complete revascularization.

This article has been cited by other articles:

				C. Q. Shi, L. H. Young, E. Daher, E. V.R. DiBella, Y.-H. Liu, E. N. Heller, S. Zoghbi, F. J.Th. Wackers, R. Soufer, and A. J. Sinusas Correlation of Myocardial p-123I-Iodophenylpentadecanoic Acid Retention with 18F-FDG Accumulation During Experimental Low-Flow Ischemia J. Nucl. Med., March 1, 2002; 43(3): 421 - 431. [Abstract] [Full Text] [PDF]

				R. O. Bonow Identification of Viable Myocardium Circulation, December 1, 1996; 94(11): 2674 - 2680. [Full Text]